Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ceapro Inc V.CZO

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human... see more

TSXV:CZO - Post Discussion

Ceapro Inc > financials ok but more to what was unsaid....
View:
Post by hoffbag on May 20, 2021 11:11am

financials ok but more to what was unsaid....

Looking through the SEDAR MDA.

Juvente still referred to as a start-up?  What is the eventual end game here?  Do they have targets?  Maybe being in competition with customers is not a good idea but I doubt they perceive Juvente as a threat....more a distraction for Ceapro.

Salaries down.  Admin.  Didnt want to move?  The team has to be growing....not shrinking!  Cost management seems good overall though.

I am having difficulty developing an image of Edmonton.  Is this a pilot facility or commercial plant? No mention on ramp up...current utilization and target revenue supportable from this operation.

Financials pretty straight forward and as previously discussed on the board except no segmentation (so fine tuning margin details difficult though Proph added).

Need to know where the Golden Gilles is taking us.  Example ... $50 million revenue in 5 years?  X number of plants?  geographic market reach?  customer base (target top 5 cosma co's)?  Product mix?  Gotta stop throwing things against the wall to see what sticks.  Invest in the man with a PLAN.

Maybe he has the "strategic vision" but it is of no use unless it is shared and contains some tangible factors.   Shareholders like to know where they are being taken (little more detail appreciated) 

Be bold!  Kudos for the sales volume up!
Comment by prophetoffacts on May 20, 2021 12:31pm
This post has been removed in accordance with Community Policy
Comment by prophetoffacts on May 20, 2021 12:58pm
This post has been removed in accordance with Community Policy
Comment by hoffbag on May 20, 2021 1:51pm
Thanks for trying to paint the picture Proph.  I think an addition to the corp presentation should be some top level thinking.  Paint the picture.  Need to communicate a clear image of what Ceapro is and where it is going so that investors can get their arms around this.  Put in market context. Simple Story! (right now my image is a mishmash of failed veterenarian products ...more  
Comment by lscfa on May 20, 2021 3:09pm
Cash flow no.s cherry picked... cash flow from ops before changes in non-cash working capital is a better indicator. Collecting trade receivables faster this year than last year says nothing about how well the ops generate cash.     $989,515 vs. $1,685,353      "Cash generated from operations of $305,000 in Q1 2021 vs. $531,000 in Q1 2020."
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities